 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12...28293031323334353637383940» |
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change: R2810-ONC-1622: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 19, 2018
P1, N=81, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=14 --> 81
- || Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Sep 17, 2018
P1, N=50, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=14 --> 81 N=30 --> 50 | Trial completion date: Jan 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2019
- | ISA101 / ISA Pharma
New P2 trial: OpcemISA: A Randomized Phase 2 Study of Cemiplimab (clinicaltrials.gov) - Sep 13, 2018
P2, N=164, Not yet recruiting, Sponsor: ISA Pharmaceuticals
- | Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Enrollment change: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Sep 11, 2018
P1, N=172, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=30 --> 50 | Trial completion date: Jan 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2019 N=318 --> 172
- | Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Enrollment change: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Sep 5, 2018
P1, N=318, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=318 --> 172 N=172 --> 318
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) - Aug 28, 2018
P1/2, N=134, Recruiting, Sponsor: Sanofi
N=172 --> 318 Trial completion date: May 2021 --> Aug 2022 | Trial primary completion date: May 2021 --> Aug 2022
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Monotherapy: EMPOWER-Lung 2: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Aug 20, 2018
P3, N=585, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: May 2021 --> Aug 2022 | Trial primary completion date: May 2021 --> Aug 2022 Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab) / Sanofi, Regeneron
Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. (Pubmed Central) - Aug 16, 2018
P1, P2
Conclusions Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT02383212 and NCT02760498 .).
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: R2810-ONC-1620: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (clinicaltrials.gov) - Aug 15, 2018
P2, N=137, Recruiting, Sponsor: Regeneron Pharmaceuticals
(Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT02383212 and NCT02760498 .). Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Jul 2018 --> Sep 2020
- ||||| ubamatamab (REGN4018) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
New P1/2 trial: R4018-ONC-1721: Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov) - Jul 15, 2018
P1/2, N=264, Recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| Libtayo (cemiplimab-rwlc) / Regeneron, REGN4659 / Regeneron
New P1 trial: Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 8, 2018
P1, N=134, Recruiting, Sponsor: Regeneron Pharmaceuticals
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: NCI-2018-01313: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery (clinicaltrials.gov) - Jul 6, 2018
P2, N=22, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Jul 2018 --> Sep 2020 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Jan 2020 | Trial primary completion date: Dec 2020 --> Jan 2020
- | Review, Journal, Checkpoint inhibition: Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. (Pubmed Central) - Jul 3, 2018
Phase II studies using anti-PD-1 molecules, nivolumab and pembrolizumab are ongoing, and GOG 3016, the first phase III randomized trial of a checkpoint inhibitor (cemiplimab) in cervical cancer, recently activated. Important considerations in attempts to inhibit the inhibitors include pseudoprogression and post-progression survival, abscopal effects, and immune-related adverse events, including endocrinopathies.
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial, PD(L)-1 Biomarker, IO biomarker: NCI-2018-01313: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery (clinicaltrials.gov) - Jun 20, 2018
P2, N=22, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jun 18, 2018
P1/2, N=52, Recruiting, Sponsor: Inovio Pharmaceuticals
Important considerations in attempts to inhibit the inhibitors include pseudoprogression and post-progression survival, abscopal effects, and immune-related adverse events, including endocrinopathies. Not yet recruiting --> Recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Enrollment change, Trial completion date, Trial primary completion date: R3767-ONC-1613: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers (clinicaltrials.gov) - Jun 15, 2018
P1, N=546, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting N=301 --> 546 | Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Jul 2019 --> Sep 2021
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jun 11, 2018
P1, N=30, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=301 --> 546 | Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Jul 2019 --> Sep 2021 Trial completion date: Aug 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> May 2019
- || Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Trial completion date, Trial primary completion date: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Jun 3, 2018
P1, N=172, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Aug 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> May 2019 Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: R2810-ONC-1622: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 2, 2018
P1, N=14, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020 Trial completion date: Aug 2019 --> Aug 2023 | Trial primary completion date: Aug 2019 --> Aug 2023
- ||| Pexa-Vec (pexastimogene devacirepvec) / SillaJen
Enrollment open: JX594-REN026: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (clinicaltrials.gov) - May 31, 2018
P1b, N=89, Recruiting, Sponsor: SillaJen, Inc.
Trial completion date: Aug 2019 --> Aug 2023 | Trial primary completion date: Aug 2019 --> Aug 2023 Not yet recruiting --> Recruiting
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P3 trial, Monotherapy: EMPOWER-Lung 2: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (clinicaltrials.gov) - May 2, 2018
P3, N=585, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: EMPOWER-Cervical 1: Study of Cemiplimab in Adults With Cervical Cancer (clinicaltrials.gov) - Apr 27, 2018
P3, N=436, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: May 2020 --> Jan 2022
- Libtayo (cemiplimab-rwlc) / Regeneron
New trial: Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 25, 2018
P=N/A, N=0, Available, Sponsor: Regeneron Pharmaceuticals
- ||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Apr 8, 2018
P1/2, N=52, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | Libtayo (cemiplimab-rwlc) / Regeneron, Yervoy (ipilimumab) / BMS
New P1 trial: Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (clinicaltrials.gov) - Mar 26, 2018
P1, N=24, Not yet recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- |||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Mar 22, 2018
P1/2, N=105, Recruiting, Sponsor: Sanofi
Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: May 2020 --> Jan 2022 Not yet recruiting --> Recruiting
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: EMPOWER-lung 4: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (clinicaltrials.gov) - Mar 15, 2018
P2, N=201, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, PD(L)-1 Biomarker: EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Mar 14, 2018
P3, N=690, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Mar 13, 2018
P1, N=6, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Suspended --> Recruiting
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial initiation date: EMPOWER-CSCC-1 : Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=182, Recruiting, Sponsor: Regeneron Pharmaceuticals
Suspended --> Recruiting Initiation date: Mar 2016 --> Mar 2016
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial suspension: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Feb 28, 2018
P1, N=6, Suspended, Sponsor: Mayo Clinic
Initiation date: Mar 2016 --> Mar 2016 Recruiting --> Suspended
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial initiation date, Trial primary completion date: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 15, 2018
P1/2, N=134, Recruiting, Sponsor: Sanofi
Recruiting --> Suspended Trial primary completion date: May 2021 --> Jul 2021 | Trial completion date: May 2021 --> Jul 2021 | Initiation date: Jan 2018 --> Jan 2018
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: EMPOWER-lung 4: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (clinicaltrials.gov) - Feb 11, 2018
P2, N=201, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Feb 8, 2018
P1, N=6, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2021 --> Jul 2021 | Trial completion date: May 2021 --> Jul 2021 | Initiation date: Jan 2018 --> Jan 2018 Active, not recruiting --> Recruiting
- | Libtayo (cemiplimab) / Sanofi, Regeneron
Journal: Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. (Pubmed Central) - Feb 3, 2018
P1
Active, not recruiting --> Recruiting These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to PD-1 blockade.
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment change, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Jan 31, 2018
P1/2, N=105, Not yet recruiting, Sponsor: Sanofi
These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to PD-1 blockade. N=54 --> 105 | Trial primary completion date: Sep 2021 --> Jan 2021
- || Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Trial primary completion date: R3767-ONC-1613: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers (clinicaltrials.gov) - Jan 12, 2018
P1, N=301, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=54 --> 105 | Trial primary completion date: Sep 2021 --> Jan 2021 Trial primary completion date: Jul 2020 --> Jul 2019
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Jan 8, 2018
P1, N=6, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jul 2020 --> Jul 2019 Suspended --> Active, not recruiting | N=24 --> 6
- |||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 22, 2017
P1/2, N=134, Recruiting, Sponsor: Sanofi
Suspended --> Active, not recruiting | N=24 --> 6 Not yet recruiting --> Recruiting
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Dec 11, 2017
P1/2, N=54, Not yet recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2020 --> Sep 2021
- ||||| Sarclisa (isatuximab-irfc) / Sanofi
New P1/2 trial: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 11, 2017
P1/2, N=134, Not yet recruiting, Sponsor: Sanofi
- || Pexa-Vec (pexastimogene devacirepvec) / SillaJen
Trial initiation date, Trial primary completion date: JX594-REN026: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (clinicaltrials.gov) - Nov 22, 2017
P1b, N=89, Not yet recruiting, Sponsor: SillaJen, Inc.
Trial primary completion date: Feb 2020 --> Sep 2021 Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Apr 2020 --> Nov 2019
- Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Nov 17, 2017
P1, N=30, Recruiting, Sponsor: Regeneron Pharmaceuticals
Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Apr 2020 --> Nov 2019 Trial primary completion date: Aug 2019 --> Sep 2018
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 14, 2017
P1, N=398, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Aug 2019 --> Sep 2018 Trial primary completion date: Jul 2019 --> Dec 2019
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 20, 2017
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Jul 2019 --> Dec 2019 Trial primary completion date: Dec 2018 --> Dec 2020
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Trial initiation date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Oct 17, 2017
P1/2, N=54, Not yet recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2018 --> Dec 2020 Initiation date: Aug 2017 --> Jan 2018
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change: EMPOWER-CSCC-1 : Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 4, 2017
P2, N=182, Recruiting, Sponsor: Regeneron Pharmaceuticals
Initiation date: Aug 2017 --> Jan 2018 N=129 --> 182
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: EMPOWER-Cervical 1: Study of Cemiplimab in Adults With Cervical Cancer (clinicaltrials.gov) - Oct 3, 2017
P3, N=436, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=129 --> 182 Not yet recruiting --> Recruiting
- ||| Pexa-Vec (pexastimogene devacirepvec) / SillaJen
New P1 trial: JX594-REN026: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (clinicaltrials.gov) - Sep 26, 2017
P1b, N=89, Not yet recruiting, Sponsor: SillaJen, Inc.
- |||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Sep 19, 2017
P1/2, N=54, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2019 --> Feb 2020